A randomized trial of a low‐dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease

• Published in: Movement disorders Vol. 32; no. 5; pp. 783 - 789
• Main Authors: Olanow, C. Warren, Kieburtz, Karl, Leinonen, Mika, Elmer, Lawrence, Giladi, Nir, Hauser, Robert A., Klepiskaya, Olga S., Kreitzman, David L., Lew, Mark F., Russell, David S., Kadosh, Shaul, Litman, Pninit, Friedman, Hadas, Linvah, Nurit, the P2B Study Group, for
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.05.2017
• Subjects: Activities of daily living; Aged; Antiparkinson Agents - therapeutic use; Benzothiazoles - therapeutic use; Clinical trials; Delayed-Action Preparations; Dopamine receptors; Double-Blind Method; Drug Combinations; Female; Humans; Indans - therapeutic use; Israel; Male; Middle Aged; Motor task performance; Movement disorders; Nausea; Neostriatum; Neurodegenerative diseases; Neuroprotective Agents - therapeutic use; P2B001; Parkinson Disease - drug therapy; Parkinson's disease; Pramipexole; Quality of life; Rasagiline; Severity of Illness Index; Triethylenemelamine; United States; P2B001; Parkinson's disease; Rasagiline; Pramipexole

ABSTRACT Background Rasagiline and pramipexole act to improve striatal dopaminergic transmission in PD via distinct and potentially synergistic mechanisms. We performed a placebo‐controlled study to determine whether 2 doses of a novel slow‐release, low‐dose combination of rasagiline and pramipexole...